Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany.
Retina. 2010 Oct;30(9):1420-5. doi: 10.1097/IAE.0b013e3181d87e97.
The purpose of this study was to evaluate the effect of intravitreally administered bevacizumab on untreated vascularized pigment epithelium detachment (PED) in sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration.
In this retrospective study, 28 untreated eyes of 26 patients (4 men, 22 women; mean age, 74.6 ± 7.2 years) with PED and sub- or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration and additional intra- and/or subretinal fluid were treated with intravitreal injections of 1.25 mg bevacizumab. Baseline and follow-up visits included best-corrected visual acuity, complete ophthalmic examination, and Stratus optical coherence tomography. Fluorescein angiography was performed at baseline. Reinjections were performed if intra- and/or subretinal fluid persisted or recurred or PED increased.
Patients received 3.2 ± 1.8 injections (follow-up 37.9 ± 18.3 weeks). Mean maximum PED height showed a tendency to decrease (372 ± 150.5 μm to 290.3 ± 189 μm; P = 0.094). In 14 eyes (53.8%), PED height was reduced at last visit, including complete flattening in 1 eye. Mean visual acuity remained stable (0.58 ± 0.30 logarithm of the minimum angle of resolution to 0.58 ± 0.37 logarithm of the minimum angle of resolution; P = 0.905). Pigment epithelium detachment response to treatment did not correlate with baseline PED height or visual acuity at baseline or at the last visit. One patient sustained a retinal pigment epithelium rip, and another patient sustained an extensive subretinal hemorrhage.
During bevacizumab therapy, mean PED height decreases in 50% of patients. No predictive factors for the response of PED to bevacizumab treatment could be identified. Treatment of PED with bevacizumab might result in a long-term functional benefit compared with the natural course.
本研究旨在评估玻璃体内注射贝伐单抗对年龄相关性黄斑变性所致亚或旁中心型隐匿性脉络膜新生血管伴未治疗的血管性色素上皮脱离(PED)的疗效。
在这项回顾性研究中,26 例患者(4 名男性,22 名女性;平均年龄 74.6 ± 7.2 岁)的 28 只未经治疗的眼患有 PED 和亚或旁中心型隐匿性脉络膜新生血管,这些病变继发于年龄相关性黄斑变性且伴有视网膜内和/或下视网膜积液。这些患者均接受玻璃体内注射 1.25mg 贝伐单抗治疗。基线和随访检查包括最佳矫正视力、全面眼科检查和 Stratus 光学相干断层扫描。基线时行荧光素血管造影。如果视网膜内和/或下视网膜积液持续或复发或 PED 增加,则进行再次注射。
患者接受了 3.2 ± 1.8 次注射(随访 37.9 ± 18.3 周)。最大 PED 高度的平均值呈下降趋势(372 ± 150.5μm 至 290.3 ± 189μm;P = 0.094)。在 14 只眼中(53.8%),PED 高度在最后一次随访时降低,包括 1 只眼完全变平。平均视力保持稳定(0.58 ± 0.30 最小角分辨率对数至 0.58 ± 0.37 最小角分辨率对数;P = 0.905)。PED 对治疗的反应与基线 PED 高度或基线和最后一次随访时的视力均无相关性。1 例患者发生视网膜色素上皮撕裂,另 1 例患者发生广泛的视网膜下出血。
在贝伐单抗治疗期间,50%的患者 PED 高度下降。未能确定 PED 对贝伐单抗治疗反应的预测因素。与自然病程相比,用贝伐单抗治疗 PED 可能会带来长期的功能获益。